Erratum in "Results of lenvatinib as first-line targeted therapy for advanced hepatocellular cancer: A retrospective study" (DOI: 10.26442/18151434.2025.2.203293)

Cover Page

Cite item

Full Text

Abstract

In the article «Results of lenvatinib as first-line targeted therapy for advanced hepatocellular cancer: A retrospective study», published in the Journal of Modern Oncology, Vol. 27, No. 2, 2025 (DOI: 10.26442/18151434.2025.2.203293), errors were made: the numerical data from Table 2 in four cells related to two columns (Median PFS and Median OS) were reversed. Data [12.7 (7.6-21.7)] were reversed with [6 (2.3-12.7)]; data [15.1 (3.9-43.8)] were reversed with [10.6 (1.8-16.1)].

Full Text

In the article «Results of lenvatinib as first-line targeted therapy for advanced hepatocellular cancer: A retrospective study», published in the Journal of Modern Oncology, Vol. 27, No. 2, 2025 (DOI: 10.26442/18151434.2025.2.203293), errors were made: the numerical data from Table 2 in four cells related to two columns (Median PFS and Median OS) were reversed. Data [12.7 (7.6-21.7)] were reversed with [6 (2.3-12.7)]; data [15.1 (3.9-43.8)] were reversed with [10.6 (1.8-16.1)].

The correct version of the table:

 

Таблица 2. Межгрупповая сравнительная оценка ОВ и ВБП

Table 2. Intergroup comparative assessment of overall survival and progression-free survival rates

Характеристика

Результат, абс. (%)

Медиана ВБП, мес (95% ДИ)

p; log-rank test

Медиана ОВ, мес (95% ДИ)

p; log-rank test

BCLC

BCLC B

16 (39,0)

10,6 (1,8–16,1)

0,028

15,2 (5,6–37,5)

0,332

BCLC C

25 (61)

6 (2,3–15,7)

12,7 (7,4–27,4)

Без цирроза

16 (39)

7,4 (1,8–16,1)

0,995

15,1 (5,6–32,7)

0,581

С циррозом

25 (61)

6,1 (2–15,7)

10,2 (7,6–43,8)

Тромбоз Vp4

Есть

9 (22)

6 (2,3–12,7)

0,108

12,7 (7,6–21,7)

0,566

Нет

32 (78)

10,6 (1,8–16,1)

15,1 (3,9–43,8)

 

The errors were corrected at the request of the authors' team. The publisher replaced the original version of the published article with the corrected one; the information on the website was also corrected.

The publisher apologizes to readers and authors for the errors and is confident that the correction of errors will ensure the correct perception and interpretation of the results of the study described in the text.

×

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2025 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 69203 от 24.03.2017 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 63964
от 18.12.2015 г.